Peptide receptor radionuclide therapy

Best Practice and Research: Clinical Gastroenterology

Volumn 19, Issue 4 SPEC. ISS., 2005, Pages 595-616

  Teunissen, Jaap J M ^a   Kwekkeboom, Dik J ^a   de Jong, Marion ^a   Esser, Jan Paul ^a   Valkema, Roelf ^a   Krenning, Eric P ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Carcinoid tumour; Neuroendocrine tumours; Radionuclides; Radiotherapy; Somatostatin receptors

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ANGIOPEPTIN; ANTIEMETIC AGENT; ARGININE; INDIUM 111; LUTETIUM; LYSINE; OCTREOTIDE; PENTETREOTIDE IN 111; RADIOISOTOPE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; YTTRIUM 90; (177LUTETIUM DOTA(O)TYR3)OCTREOTATE; (177LUTETIUM-DOTA(O)TYR3)OCTREOTATE; CYCLOPEPTIDE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; INDIUM; OCTREOTATE, TYR(3); OCTREOTATE, TYR(3)-; ORGANOMETALLIC COMPOUND; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; RECEPTOR; SDZ 215 811; SDZ 215-811; SOMATOSTATIN; YTTRIUM;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; HYPERKALEMIA; ISOTOPE LABELING; KIDNEY DISEASE; LEUKEMIA; LIVER TOXICITY; METASTASIS POTENTIAL; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; NONHUMAN; RADIATION DOSE; REVIEW; SCINTIGRAPHY; TREATMENT INDICATION; TREATMENT OUTCOME; VOMITING; ANIMAL; CARCINOMA; GASTROINTESTINAL TUMOR; METASTASIS; PANCREAS TUMOR; PATHOLOGY; PATIENT SELECTION; QUALITY OF LIFE; SCINTISCANNING;

ANIMALS; CARCINOMA, NEUROENDOCRINE; GASTROINTESTINAL NEOPLASMS; HUMANS; INDIUM RADIOISOTOPES; LUTETIUM; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PANCREATIC NEOPLASMS; PATIENT SELECTION; PENTETIC ACID; PEPTIDES, CYCLIC; QUALITY OF LIFE; RADIOPHARMACEUTICALS; RECEPTORS, PEPTIDE; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 26844442315     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bpg.2005.04.001     Document Type: Review

References (70)

1. E.P. Krenning D.J. Kwekkeboom W.H. Bakker et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients Eur J Nucl Med 20 1993 716-731
2. D. Kwekkeboom E.P. Krenning & M. de Jong Peptide receptor imaging and therapy J Nucl Med 41 2000 1704-1713
3. P. Andersson E. Forssell-Aronsson V. Johanson et al. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide J Nucl Med 37 1996 2002-2006
4. L.J. Hofland P.M. van Koetsveld & M. Waaijers Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: Increase by unlabeled octreotide Endocrinology 136 1995 3698-3706
5. M. de Jong W.A. Breeman W.H. Bakker et al. Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy Cancer Res 58 1998 437-441
6. R. Valkema M. De Jong W.H. Bakker et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: The Rotterdam experience Semin Nucl Med 32 2002 110-122
7. K.E. McCarthy E.A. Woltering & L.B. Anthony In situ radiotherapy with 111In-pentetreotid. State of the art and perspectives Q J Nucl Med 44 2000 88-95
8. E.P. Krenning P.P. Kooij W.H. Bakker et al. Radiotherapy with a radiolabeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case history Ann N Y Acad Sci 733 1994 496-506
9. A. Capello E.P. Krenning W.A. Breeman et al. Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]octreotide J Nucl Med 44 2003 98-104
10. E.P. Krenning M. de Jong P.P. Kooij et al. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy Ann Oncol 10 supplement 2 1999 S23-S29
11. M.C. Smith J. Liu T. Chen et al. OctreoTher: Ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy Digestion 62 supplement 1 2000 69-72
12. J.A. O'Donoghue M. Bardies & T.E. Wheldon Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides J Nucl Med 36 1995 1902-1909
13. J.C. Reubi B. Waser J.A. Foekens et al. Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to EGF receptors Int J Cancer 46 1990 416-420
14. R. de Jong F. Valkema R. Jamar et al. Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings Semin Nucl Med 32 2002 133-140
15. I. Virgolini K. Britton J. Buscombe et al. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial Semin Nucl Med 32 2002 148-155
16. C. Waldherr M. Pless H.R. Maecke et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC J Nucl Med 43 2002 610-616
17. D.J. Kwekkeboom W.H. Bakker B.L. Kam et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate Eur J Nucl Med Mol Imaging 30 2003 417-422
18. M. de Jong W.A. Breeman B.F. Bernard et al. Receptor-targeted radionuclide therapy using radiolabelled somatostatin analogues: Tumour size versus curability J Nucl Med 28 2001 1026 (abstract)
19. M. de Jong W.A. Breeman B.F. Bernard et al. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size J Nucl Med 42 2001 1841-1846
20. M. de Jong W.A.P. Breeman R. Valkema et al. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs J Nucl Med 46 2005 13S-17S
21. L. Rohrer F. Raulf C. Bruns et al. Cloning and characterization of a fourth human somatostatin receptor Proc Natl Acad Sci USA 90 1993 4196-4200
22. R. Panetta M.T. Greenwood A. Warszynska et al. Molecular cloning, functional characterization, and chromosomal localization of a human somatostatin receptor (somatostatin receptor type 5) with preferential affinity for somatostatin-28 Mol Pharmacol 45 1994 417-427
23. Y. Yamada S.R. Post K. Wang et al. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney Proc Natl Acad Sci USA 89 1992 251-255
24. J.F. Bruno & M. Berelowitz Somatostatin teceptors: Orphan that found family and function Mol Cell Neurosci 4 1993 307-309
25. Y. Yamada S. Kagimoto A. Kubota et al. Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype Biochem Biophys Res Commun 195 1993 844-852
26. J.C. Reubi J.C. Schar B. Waser et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use Eur J Nucl Med 27 2000 273-282
27. L.J. Hofland S.W.J. Lamberts P.M. van Hagen et al. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs J Nucl Med 44 2003 1315-1321
28. M. John W. Meyerhof D. Richter et al. Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2 Gut 38 1996 33-39
29. Kwekkeboom DJ, Bakker WH, Kooij PP et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients 2001; 28: 1319-1325.
30. L.B. Anthony E.A. Woltering G.D. Espenan et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies Semin Nucl Med 32 2002 123-132
31. J.R. Buscombe M.E. Caplin & A.J. Hilson Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors J Nucl Med 44 2003 1-6
32. G.D. Slooter W.A. Breeman R.L. Marquet et al. Anti-proliferative effect of radiolabelled octreotide in a metastases model in rat liver Int J Cancer 81 1999 767-771
33. A. Otte J. Mueller-Brand S. Dellas et al. Yttrium-90-labelled somatostatin-analogue for cancer treatment Lancet 351 1998 417-418
34. C. Waldherr M. Pless H.R. Maecke et al. The clinical value of [90Y-DOTA]-DPhe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: A clinical phase II study Ann Oncol 12 2001 941-945
35. C. Waldherr T. Schumacher H.R. Macke et al. Does tumor response depend on the number of treatment sessions at constant injected dose using 90Yttrium-DOTATOC in neuroendocrine tumors? Eur J Nucl Med 29 2002 S100
36. M. Chinol L. Bodei M. Cremonesi & G. Paganelli Receptor-mediated radiotherapy with Y-DOTA-DPhe-Tyr-octreotide: The experience of the European Institute of Oncology Group Semin Nucl Med 32 2002 141-147
37. G. Paganelli L. Bodei D. Handkiewicz Junak et al. 90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies Biopolymers 66 2002 393-398
38. G. Paganelli S. Zoboli M. Cremonesi et al. Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide Eur J Nucl Med 28 2001 426-434
39. L. Bodei M. Cremonesi S. Zoboli et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: A phase I study Eur J Nucl Med Mol Imaging 30 2003 207-216
40. L. Bodei M. Cremonesi C. Grana et al. Receptor radionuclide therapy with (90)Y-[DOTA](0)-Tyr(3)-octreotide ((90)Y-DOTATOC) in neuroendocrine tumours Eur J Nucl Med Mol Imaging 31 2004 1038-1046
41. R. Valkema S. Pauwels L. Kvols et al. Long-term follow-up of a phase 1 study of peptide receptor radionuclide therapy (PRRT) with (90Y-DOTA0,Tyr3)octreotide in patients with somatostatin receptor positive tumours Eur J Nucl Med 30 supplement 2 2003 S232
42. R. Valkema S. Pauwels L. Kvols et al. Survival in patients with neuroendocrine tumors after treatment with [90Y-DOTA,Tyr) in a phase-1 study J Nucl Med 44 supplement 2 2003 136P
43. R.P. Baum J. Soldner M. Schmucking & A. Niesen Intravenous and intra-arterial peptide receptor radionuclide therapy (PRRT) using Y-90-DOTA-Tyr3-octreotate (Y-90-DOTA-TATE) in patients with metastatic neuroendocrine tumors Eur J Nucl Med 31 supplement 2 2004 S238 (abstract)
44. R.P. Baum J. Söldner M. Schmüching & A. Niesen Peptidrezeptorvermittelte Radiotherapie (PRRT) neuroendokriner Tumoren Klinischen Indikationen und Erfahrung mit 90Yttrium-markierten Somatostatinanaloga Der Onkologe 10 2004 1098-1110
45. D.J. Kwekkeboom W.H. Bakker J.J. Teunissen et al. Treatment with Lu-177-DOTA-Tyr3-octreotate in patients with neuroendocrine tumors: interim results Eur J Nucl Med Mol Imaging 30 supplement 2 2003 S231 (abstract)
46. Kwekkeboom DJ, Teunissen JJ, Bakker WH et al. Radiolabelled somatostatin analog [177Lu-DOTAO, Tyr3]octreotate in patients with endocrine gastro entero pancreatic tumors. J Clin Oncol 2005; 23: 2754-2762.
47. R. Valkema L. Kvols F. Jamar et al. Phase 1 study of therapy with 90Y-SMT487 (OctreoTher) in patients with somatostatin receptor (SS-R) positive tumors J Nucl Med 43 supplement 2002 33P
48. A. Otte R. Herrmann A. Heppeler et al. Yttrium-90 DOTATOC: First clinical results Eur J Nucl Med 26 1999 1439-1447
49. W.H. Bakker E.P. Krenning J.C. Reubi et al. In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats Life Sci 49 1991 1593-1601
50. E.P. Krenning W.H. Bakker P.P. Kooij et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: Metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide J Nucl Med 33 1992 652-658
51. B. Emami J. Lyman A. Brown et al. Tolerance of normal tissue to therapeutic irradiation Int J Radiat Oncol Biol Phys 21 1991 109-122
52. S. Moll V. Nickeleit J. Mueller-Brand et al. A new cause of renal thrombotic microangiopathy: Yttrium 90-DOTATOC internal radiotherapy Am J Kidney Dis 37 2001 847-851
53. M. Cybulla S.M. Weiner & A. Otte End-stage renal disease after treatment with 90Y-DOTATOC Eur J Nucl Med 28 2001 1552-1554
54. M.P. Stoffel M. Pollok J. Fries & C.A. Baldamus Radiation nephropathy after radiotherapy in metastatic medullary thyroid carcinoma Nephrol Dial Transplant 16 2001 1082-1083
55. R. Barone F. Borson-Chazot R. Valkema et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship J Nucl Med 46 2005 99S-106S
56. R. Valkema S.A. Pauwels L.K. Kvols et al. Long-term follow-up of renal function after peptide receptor radiation therapy with 90Y-DOTA0,Tyr3-octreotide and 177Lu-DOTA0, Tyr3-octreotate J Nucl Med 46 2005 83S-91S
57. M. de Jong E.J. Rolleman B.F. Bernard et al. Inhibition of renal uptake of indium-111-DTPA-octreotide in vivo J Nucl Med 37 1996 1388-1392
58. F. Jamar R. Barone I. Mathieu et al. 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)-a phase 1 clinical study: Pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion Eur J Nucl Med Mol Imaging 30 2003 510-518
59. E.J. Rolleman R. Valkema M. de Jong et al. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine Eur J Nucl Med Mol Imaging 30 2003 9-15
60. R. Barone S. Pauwels J. De Camps et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues Nephrol Dial Transplant 19 2004 2275-2281
61. D. Bushnell Y. Menda M. Madsen et al. Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastases Cancer Biother Radiopharm 18 2003 581-588
62. S. Toth-Fejel & R.F. Pommier Relationships among delay of diagnosis, extent of disease, and survival in patients with abdominal carcinoid tumors Am J Surg 187 2004 575-579
63. M. de Jong D. Kwekkeboom R. Valkema & E.P. Krenning Radiolabelled peptides for tumour therapy: Current status and future directions. Plenary lecture at the EANM 2002 Eur J Nucl Med Mol Imaging 30 2003 463-469
64. C. Sanders M. Egger J. Donovan et al. Reporting on quality of life in randomised controlled trials: Bibliographic study BMJ (Clin Res Ed.) 317 1998 1191-1194
65. D. Bushnell T. O'Dorisio Y. Menda et al. Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors J Nucl Med 44 2003 1556-1560
66. J.J. Teunissen D.J. Kwekkeboom & E.P. Krenning Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate J Clin Oncol 22 2004 2724-2729
67. D. Wild J.S. Schmitt M. Ginj et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals Eur J Nucl Med Mol Imaging 30 2003 1338-1347
68. M. Béhé M. Pusken M. Henzel et al. Upregulation of gastrin and somatostatin receptor after irradiation Eur J Nucl Med 44 supplement 2 2003 S218
69. J.C. Reubi & B. Waser Concomitant expression of several peptide receptors in neuroendocrine tumours: Molecular basis for in vivo multireceptor tumour targeting Eur J Nucl Med Mol Imaging 30 2003 781-793
70. J.W.G. van Putten A. Price A.H.D. van der Leest et al. A phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer Clin Cancer Res 9 2003 2472-2477